Total words: 2202 | 2-word phrases: 584 | 3-word phrases: 651 | 4-word phrases: 675
PAGE INFO
Title | Try to keep the title under 60 characters (9 characters) Maven Bio |
Description | Try to keep the meta description between 50 - 160 characters (38 characters) AI-enabled BioPharma Industry Research |
Keywords | Meta keywords are not recommended anymore (0 characters)
|
H1 | H1 tag on the page (49 characters) Your AI analyst for BioPharma market intelligence |
ONE WORD PHRASES 292 Words
# |
Keyword |
H1 |
Title |
Des |
Volume |
Position |
Suggest |
Frequency |
Density |
1 | of | | | | | | | 26 | 8.90% |
2 | a | | | | | | | 23 | 7.88% |
3 | your | | | | | | | 23 | 7.88% |
4 | the | | | | | | | 23 | 7.88% |
5 | and | | | | | | | 22 | 7.53% |
6 | to | | | | | | | 22 | 7.53% |
7 | on | | | | | | | 21 | 7.19% |
8 | landscape | | | | | | | 20 | 6.85% |
9 | analysis | | | | | | | 18 | 6.16% |
10 | focus | | | | | | | 16 | 5.48% |
TWO WORD PHRASES 584 Words
# |
Keyword |
H1 |
Title |
Des |
Volume |
Position |
Suggest |
Frequency |
Density |
1 | landscape analysis | | | | | | | 8 | 1.37% |
2 | maven bio | | | | | | | 7 | 1.20% |
3 | maven bio? | | | | | | | 7 | 1.20% |
4 | our ai | | | | | | | 7 | 1.20% |
5 | ai analyst | | | | | | | 6 | 1.03% |
6 | custom landscape | | | | | | | 6 | 1.03% |
7 | to your | | | | | | | 6 | 1.03% |
8 | smart on | | | | | | | 5 | 0.86% |
9 | like to | | | | | | | 5 | 0.86% |
10 | based on | | | | | | | 5 | 0.86% |
11 | will result | | | | | | | 4 | 0.68% |
12 | focus on | | | | | | | 4 | 0.68% |
13 | the column | | | | | | | 4 | 0.68% |
14 | get smart | | | | | | | 4 | 0.68% |
15 | included in | | | | | | | 4 | 0.68% |
16 | in the | | | | | | | 4 | 0.68% |
17 | consider all | | | | | | | 4 | 0.68% |
18 | define your | | | | | | | 4 | 0.68% |
19 | a focus | | | | | | | 4 | 0.68% |
20 | companies drugs | | | | | | | 4 | 0.68% |
THREE WORD PHRASES 651 Words
# |
Keyword |
H1 |
Title |
Des |
Volume |
Position |
Suggest |
Frequency |
Density |
1 | our ai analyst | | | | | | | 5 | 0.77% |
2 | included in the | | | | | | | 4 | 0.61% |
3 | specific areas of | | | | | | | 4 | 0.61% |
4 | depth vs breadth | | | | | | | 4 | 0.61% |
5 | get smart on | | | | | | | 4 | 0.61% |
6 | will result in | | | | | | | 4 | 0.61% |
7 | breadth will result | | | | | | | 4 | 0.61% |
8 | on breadth will | | | | | | | 4 | 0.61% |
9 | a focus on | | | | | | | 4 | 0.61% |
10 | areas of focus | | | | | | | 4 | 0.61% |
11 | based on your | | | | | | | 4 | 0.61% |
12 | focus on breadth | | | | | | | 4 | 0.61% |
13 | custom landscape analysis | | | | | | | 4 | 0.61% |
14 | get a demo | | | | | | | 3 | 0.46% |
15 | built to your | | | | | | | 3 | 0.46% |
16 | help you get | | | | | | | 3 | 0.46% |
17 | to help you | | | | | | | 3 | 0.46% |
18 | you’d like to | | | | | | | 3 | 0.46% |
19 | lists of companies | | | | | | | 3 | 0.46% |
20 | for the column | | | | | | | 3 | 0.46% |
21 | of companies drugs | | | | | | | 3 | 0.46% |
22 | the areas you | | | | | | | 3 | 0.46% |
23 | of different approaches | | | | | | | 2 | 0.31% |
24 | optional calibrate the | | | | | | | 2 | 0.31% |
25 | breadth of analysis | | | | | | | 2 | 0.31% |
26 | within specific geographies | | | | | | | 2 | 0.31% |
27 | vs breadth of | | | | | | | 2 | 0.31% |
28 | activity within specific | | | | | | | 2 | 0.31% |
29 | on activity within | | | | | | | 2 | 0.31% |
30 | analysis on activity | | | | | | | 2 | 0.31% |
FOUR WORD PHRASES 675 Words
# |
Keyword |
H1 |
Title |
Des |
Volume |
Position |
Suggest |
Frequency |
Density |
1 | breadth will result in | | | | | | | 4 | 0.59% |
2 | specific areas of focus | | | | | | | 4 | 0.59% |
3 | a focus on breadth | | | | | | | 4 | 0.59% |
4 | on breadth will result | | | | | | | 4 | 0.59% |
5 | focus on breadth will | | | | | | | 4 | 0.59% |
6 | to help you get | | | | | | | 3 | 0.44% |
7 | lists of companies drugs | | | | | | | 3 | 0.44% |
8 | our ai will research | | | | | | | 2 | 0.30% |
9 | themes and analysis of | | | | | | | 2 | 0.30% |
10 | each record in your | | | | | | | 2 | 0.30% |
11 | when deciding if an | | | | | | | 2 | 0.30% |
12 | will result in a | | | | | | | 2 | 0.30% |
13 | class product type or | | | | | | | 2 | 0.30% |
14 | drug class product type | | | | | | | 2 | 0.30% |
15 | target drug class product | | | | | | | 2 | 0.30% |
16 | mechanism target drug class | | | | | | | 2 | 0.30% |
17 | indication mechanism target drug | | | | | | | 2 | 0.30% |
18 | harsher filter when deciding | | | | | | | 2 | 0.30% |
19 | filter when deciding if | | | | | | | 2 | 0.30% |
20 | select the areas youd | | | | | | | 2 | 0.30% |
21 | identification of key development | | | | | | | 2 | 0.30% |
22 | you can select by | | | | | | | 2 | 0.30% |
23 | areas youd like to | | | | | | | 2 | 0.30% |
24 | asset should be included | | | | | | | 2 | 0.30% |
25 | optional calibrate the depthof | | | | | | | 2 | 0.30% |
26 | analysis conversely a focus | | | | | | | 2 | 0.30% |
27 | provide a short title | | | | | | | 2 | 0.30% |
28 | a short title for | | | | | | | 2 | 0.30% |
29 | short title for your | | | | | | | 2 | 0.30% |
30 | title for your report | | | | | | | 2 | 0.30% |
31 | be included in the | | | | | | | 2 | 0.30% |
32 | should be included in | | | | | | | 2 | 0.30% |
33 | an asset should be | | | | | | | 2 | 0.30% |
34 | landscape you can select | | | | | | | 2 | 0.30% |
35 | if an asset should | | | | | | | 2 | 0.30% |
36 | deciding if an asset | | | | | | | 2 | 0.30% |
37 | choose how you’d like | | | | | | | 2 | 0.30% |
38 | how you’d like to | | | | | | | 2 | 0.30% |
39 | you’d like to define | | | | | | | 2 | 0.30% |
40 | like to define your | | | | | | | 2 | 0.30% |
EXTERNAL LINKS